Cited 72 times in
Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤채옥 | - |
dc.date.accessioned | 2019-11-11T05:21:55Z | - |
dc.date.available | 2019-11-11T05:21:55Z | - |
dc.date.issued | 2000 | - |
dc.identifier.issn | 1522-8002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/171812 | - |
dc.description.abstract | Immunoglobulin T-cell receptors (IgTCRs) combine the specificity of antibodies with the potency of cellular killing by grafting antibody recognition domains onto TCR signaling chains. IgTCR-modified T cells are thus redirected to kill tumor cells based on their expression of intact antigen on cell surfaces, bypassing the normal mechanism of activation through TCR-peptide-major histocompatibility complex (MHC) recognition. Melanoma is one of the most immunoresponsive of human cancers and has served as a prototype for the development of a number of immunotherapies. The target antigen for this study is the ganglioside GD3, which is highly expressed on metastatic melanoma with only minor immunologic cross-reaction with normal tissues. To determine an optimal configuration for therapy, four combinations of IgTCRs were prepared and studied: sFv-epsilon, sFv-zeta, Fab-epsilon, Fab-zeta. These were expressed on the surface of human T cells by retroviral transduction. IgTCR successfully redirected T-cell effectors in an MHC-unrestricted manner, in this case against a non-T-dependent antigen, with specific binding, activation, and cytotoxicity against GD3+ melanoma cells. Soluble GD3 in concentrations up to 100 microg/ml did not interfere with recognition and binding of membrane-bound antigen. Based on the outcomes of these structural and functional tests, the sFv-zeta construct was selected for clinical development. These results demonstrate key features that emphasize the potential of anti-GD3 IgTCR-modified autologous T cells for melanoma therapies. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Neoplasia Press | - |
dc.relation.isPartOf | Neoplasia | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antibodies, Monoclonal/genetics | - |
dc.subject.MESH | Antibodies, Monoclonal/immunology* | - |
dc.subject.MESH | Antigens, Neoplasm/immunology* | - |
dc.subject.MESH | Binding Sites | - |
dc.subject.MESH | Cell Line | - |
dc.subject.MESH | Chemotaxis, Leukocyte/physiology* | - |
dc.subject.MESH | Cytotoxicity, Immunologic | - |
dc.subject.MESH | Gangliosides/immunology* | - |
dc.subject.MESH | Genes, Immunoglobulin | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulin Fab Fragments/genetics | - |
dc.subject.MESH | Immunoglobulin Fab Fragments/immunology | - |
dc.subject.MESH | Immunoglobulin Fragments/genetics | - |
dc.subject.MESH | Immunoglobulin Fragments/immunology | - |
dc.subject.MESH | Immunoglobulin Variable Region/genetics | - |
dc.subject.MESH | Immunoglobulin Variable Region/immunology | - |
dc.subject.MESH | Immunotherapy, Adoptive | - |
dc.subject.MESH | Interleukin-2/biosynthesis | - |
dc.subject.MESH | Jurkat Cells | - |
dc.subject.MESH | Kidney | - |
dc.subject.MESH | Melanoma/immunology* | - |
dc.subject.MESH | Membrane Proteins/genetics | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Receptors, Antigen, T-Cell/genetics | - |
dc.subject.MESH | Receptors, Antigen, T-Cell/immunology* | - |
dc.subject.MESH | Recombinant Fusion Proteins/genetics | - |
dc.subject.MESH | Recombinant Fusion Proteins/immunology | - |
dc.subject.MESH | T-Lymphocytes, Cytotoxic/cytology* | - |
dc.subject.MESH | T-Lymphocytes, Cytotoxic/immunology | - |
dc.subject.MESH | Transfection | - |
dc.title | Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors | - |
dc.type | Article | - |
dc.contributor.college | Research Institutes (연구소) | - |
dc.contributor.department | Institute for Cancer Research (암연구소) | - |
dc.contributor.googleauthor | C.O Yun | - |
dc.contributor.googleauthor | K. F. Nolan | - |
dc.contributor.googleauthor | E.J. Beecham | - |
dc.contributor.googleauthor | R.A. Reisfeld | - |
dc.contributor.googleauthor | P. Junghans | - |
dc.identifier.doi | 10.1038/sj.neo.7900108 | - |
dc.contributor.localId | A02614 | - |
dc.relation.journalcode | J02312 | - |
dc.identifier.eissn | 1476-5586 | - |
dc.identifier.pmid | 11191112 | - |
dc.subject.keyword | T-Cell | - |
dc.subject.keyword | Gene Therapy | - |
dc.subject.keyword | Immunotherapy | - |
dc.subject.keyword | Signalling | - |
dc.contributor.alternativeName | Yun, Chae Ok | - |
dc.contributor.affiliatedAuthor | 윤채옥 | - |
dc.citation.volume | 2 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 449 | - |
dc.citation.endPage | 459 | - |
dc.identifier.bibliographicCitation | Neoplasia, Vol.2(5) : 449-459, 2000 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.